<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Obstet Gynecol</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Obstet. Gynecol</journal-id><journal-title-group><journal-title>American Journal of Obstetrics and Gynecology</journal-title></journal-title-group><issn pub-type="ppub">0002-9378</issn><issn pub-type="epub">1097-6868</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29031892</article-id><article-id pub-id-type="pmc">5723571</article-id><article-id pub-id-type="publisher-id">S0002-9378(17)31185-7</article-id><article-id pub-id-type="doi">10.1016/j.ajog.2017.10.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Conroy</surname><given-names>Andrea L.</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>McDonald</surname><given-names>Chloe R.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Gamble</surname><given-names>Joel L.</given-names></name><degrees>BSc</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Olwoch</surname><given-names>Peter</given-names></name><degrees>BSc</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Natureeba</surname><given-names>Paul</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Cohan</surname><given-names>Deborah</given-names></name><degrees>MD, MPH</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Kamya</surname><given-names>Moses R.</given-names></name><degrees>MD, PhD</degrees><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Havlir</surname><given-names>Diane V.</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Dorsey</surname><given-names>Grant</given-names></name><degrees>MD, PhD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Kain</surname><given-names>Kevin C.</given-names></name><degrees>MD</degrees><email>kevin.kain@uhn.ca</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN</aff><aff id="aff2"><label>b</label>SAR Laboratories, Sandra Rotman Center for Global Health, University Health Network&#x02013;Toronto General Hospital, University of Toronto, Toronto, Canada</aff><aff id="aff3"><label>c</label>Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Canada</aff><aff id="aff4"><label>d</label>Makerere University&#x02013;University of California&#x02013;San Francisco Research Collaboration, Kampala, Uganda</aff><aff id="aff5"><label>e</label>Makerere University College of Health Sciences, Kampala, Uganda</aff><aff id="aff6"><label>f</label>Department of Obstetrics and Gynecology, University of California&#x02013;San Francisco, San Francisco, CA</aff><aff id="aff7"><label>g</label>HIV/AIDS Division, San Francisco General Hospital, San Francisco, CA</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author: Kevin C. Kain, MD. <email>kevin.kain@uhn.ca</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0030">These authors contributed equally to this article.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><month>12</month><year>2017</year></pub-date><volume>217</volume><issue>6</issue><fpage>684.e1</fpage><lpage>684.e17</lpage><history><date date-type="received"><day>7</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>22</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>1</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Author(s)</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Angiogenic processes in the placenta are critical regulators of fetal growth and impact birth outcomes, but there are limited data documenting these processes in HIV-infected women or women from low-resource settings.</p></sec><sec><title>Objective</title><p>We sought to determine whether angiogenic factors are associated with adverse birth outcomes in HIV-infected pregnant women started on antiretroviral therapy.</p></sec><sec><title>Study Design</title><p>This is a secondary analysis of samples collected as part of a clinical trial randomizing pregnant women and adolescents infected with HIV to lopinavir/ritonavir-based (n&#x000a0;= 166) or efavirenz-based (n&#x000a0;= 160) antiretroviral therapy in Tororo, Uganda. Pregnant women living with HIV were enrolled between 12-28 weeks of gestation. Plasma samples were evaluated for angiogenic biomarkers (angiopoietin-1, angiopoietin-2, vascular endothelial growth factor, soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin) by enzyme-linked immunosorbent assay between: 16-&#x0003c;20, 20-&#x0003c;24, 24-&#x0003c;28, 28-&#x0003c;32, 32-&#x0003c;36, 36-&#x0003c;37 weeks of gestation. The primary outcome was preterm birth.</p></sec><sec><title>Results</title><p>In all, 1115 plasma samples from 326 pregnant women and adolescents were evaluated. There were no differences in angiogenic factors according to antiretroviral therapy group (<italic>P</italic> &#x0003e; .05 for all). The incidence of adverse birth outcomes was 16.9% for spontaneous preterm births, 25.6% for small-for-gestational-age births, and 2.8% for stillbirth. We used linear mixed effect modelling to evaluate longitudinal changes in angiogenic factor concentrations between birth outcome groups adjusting for gestational age at venipuncture, maternal age, body mass index, gravidity, and the interaction between treatment arm and gestational age. Two angiogenic factors&#x02013;soluble endoglin and placental growth factor&#x02013;were associated with adverse birth outcomes. Significantly higher concentrations of soluble endoglin throughout gestation were found in study participants destined to deliver preterm [likelihood ratio test, &#x003c7;<sup>2</sup>(1)&#x000a0;= 12.28, <italic>P</italic>&#x000a0;&#x0003c; .0005] and in those destined to have stillbirths [&#x003c7;<sup>2</sup>(1)&#x000a0;= 5.67, <italic>P</italic>&#x000a0;&#x0003c; .02]. By contrast, significantly lower concentrations of placental growth factor throughout gestation were found in those destined to have small-for-gestational-age births [&#x003c7;<sup>2</sup>(1)&#x000a0;= 7.89, <italic>P</italic> &#x0003c; .005] and in those destined to have stillbirths [&#x003c7;<sup>2</sup>(1)&#x000a0;= 21.59, <italic>P</italic> &#x0003c; .0001].</p></sec><sec><title>Conclusion</title><p>An antiangiogenic state in the second or third trimester is associated with adverse birth outcomes, including stillbirth in women and adolescents living with HIV and receiving antiretroviral therapy.</p></sec></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>angiogenesis</kwd><kwd>HIV-1</kwd><kwd>placental growth factor</kwd><kwd>pregnancy</kwd><kwd>preterm birth</kwd><kwd>small for gestational age</kwd><kwd>soluble endoglin</kwd><kwd>soluble fms-like tyrosine kinase-1</kwd><kwd>stillbirth</kwd></kwd-group></article-meta></front><body><p id="p0010a"><boxed-text id="dtbox1"><p id="p0017">Click <underline>Supplemental Materials</underline> and <underline>Video</underline> under article title in Contents at <ext-link ext-link-type="uri" xlink:href="http://ajog.org" id="interref0010a"><bold>ajog.org</bold></ext-link></p></boxed-text></p><sec id="sec1"><title>Introduction</title><p id="p0010">It is estimated that 17.8 million of 36.7 million people living with HIV in 2015 were women and girls of reproductive age (&#x0003e;15 years).<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Widespread use of combined antiretroviral treatment (ART) has dramatically reduced rates of vertical transmission while improving maternal health and birth outcomes. However, rates of adverse birth outcomes&#x02013;including preterm birth (PTB), small for gestational age (SGA), and stillbirth&#x02013;remain higher among women and adolescents living with HIV (WLHIV) receiving ART than HIV-uninfected women.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref> There are few studies investigating the mechanisms associated with adverse birth outcomes in pregnant WLHIV. As the number of pregnant WLHIV having children increases,<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> it is important to understand the disease processes underlying adverse birth outcomes that, in turn, may facilitate improved clinical management. Recently, HIV was identified as a risk factor for maternal vascular malperfusion in a population of South African women.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></p><p id="p0015">Robust placental function is essential for fetal growth and development. Vasculogenic processes in the first trimester regulate de novo formation and growth of blood vessels. Angiogenic processes beginning in the second trimester induce remodeling of the underlying placental architecture to allow for increased blood flow and surface area for nutrient exchange.<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref> Altered expression of angiogenic factors is associated with a&#x000a0;number of complications in pregnancy&#x000a0;including preeclampsia,<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref> systemic lupus erythematosus and/or antiphospholipid antibodies,<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> fetal growth restriction,<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref> preterm delivery,<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> and spontaneous abortion/stillbirth,<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref> suggesting placental stress responses triggered by placental malperfusion can lead to systemic changes in angiogenic factors.<xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref></p><p id="p0020">The vascular endothelial growth factor (VEGF) family of proteins, including placental growth factor (PlGF), are proangiogenic mediators that are synthesized by trophoblast, and endothelial cells of the placental villi. VEGF and PlGF bind VEGF receptor 1 (fms-like tyrosine kinase [Flt]-1) and VEGF binds VEGF receptor 2 on&#x000a0;the&#x000a0;endothelium to induce vascular proliferation, migration, and sprouting.<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref> Flt-1 can be alternatively spliced to generate the antiangiogenic protein soluble Flt (sFlt)-1.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> The angiopoietins (Ang) bind their cognate receptor, tyrosine-protein kinase Tie-2. Ang-1 induces maturation and stabilization of&#x000a0;the vasculature while Ang-2 generally causes destabilization and induces angiogenesis.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Soluble endoglin (sEng) is a soluble receptor of transforming growth&#x000a0;factor (TGF)-&#x003b2; that binds TGF-&#x003b2;&#x000a0;and reduces its bioavailability.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> sEng appears to inhibit the immunoregulatory actions of TGF-&#x003b2; and acts as an&#x000a0;antiangiogenic factor in the placenta by&#x000a0;inhibiting vascular permeability and nitric-oxide-mediated vasodilation.<xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref></p><p id="p0025">Angiogenic processes in the placenta affect pregnancy, but there are limited data documenting these processes in the context of HIV infection and low-resource settings where rates of adverse birth outcomes are the highest. We hypothesize that alterations in angiogenic factors are associated with adverse birth&#x000a0;outcomes in pregnant WLHIV. To test this hypothesis we longitudinally characterized circulating plasma levels of angiogenic proteins in a cohort of WLHIV initiated on ART.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> In this report we describe the kinetics of angiogenic factors over pregnancy, compare angiogenic factors between&#x000a0;different ART regimens (efavirenz- vs lopinavir/ritonavir-based ART), and evaluate whether angiogenic factors predict adverse birth outcomes (spontaneous PTB, SGA, and stillbirth).</p></sec><sec id="sec2"><title>Materials and Methods</title><sec id="sec2.1"><title>Ethics statement</title><p id="p0030">Written informed consent was obtained from all participants. Ethical approval was received from Makerere University School of Medicine (Sept. 20, 2009; reference 2009-141); the Uganda National Council for Science and Technology; the University of California&#x02013;San Francisco (Aug. 9, 2009; reference 10-02958); and the University Health Network (March 13, 2014; reference 14-7313-AE). This trial was registered: <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0010">ClinicalTrials.gov</ext-link> (identifier: <ext-link ext-link-type="uri" xlink:href="ctgov:NCT00993031" id="intref0015">NCT00993031</ext-link>).</p></sec><sec id="sec2.2"><title>Study population</title><p id="p0035">Plasma samples were collected from pregnant WLHIV participating in a randomized controlled trial of protease inhibitor vs nonnucleoside reverse transcriptase inhibitor&#x02013;based ART in Tororo, Uganda, from 2009 through 2013.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Participants were HIV-infected, &#x02265;16 years of age, and pregnant (12-28 weeks of gestation by last menstrual period with confirmation by ultrasound). Eligibility for enrollment was not dependent on CD4 cell count. Patients were ineligible to participate if&#x000a0;they had received ART (including any&#x000a0;abbreviated monotherapy) or dual therapy with nevirapine in the last 24&#x000a0;months. Subjects received standard antenatal care according to Ugandan Ministry of Health Guidelines (<ext-link ext-link-type="uri" xlink:href="http://www.health.go.ug/docs/ucg_2010.pdf" id="intref0020">http://www.health.go.ug/docs/ucg_2010.pdf</ext-link>). Blood pressure and urine protein was assessed at enrollment and routine antenatal visits. Participants on protease inhibitor&#x02013;based ART received lopinavir/ritonavir (n&#x000a0;= 166) and those on nonnucleoside reverse transcriptase inhibitor&#x02013;based ART received efavirenz (n&#x000a0;= 160). Socioeconomic status was assessed as described.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref></p></sec><sec id="sec2.3"><title>Laboratory assays</title><p id="p0040">Blood collection and laboratory work was performed at baseline and at all subsequent antenatal visits. Clinical tests&#x000a0;included complete blood cell count&#x000a0;and&#x000a0;determination of CD4<sup>+</sup>/CD8<sup>+</sup> T-lymphocyte subsets. Standardized assessments were completed at delivery including gestational age and birthweight (using an electronic scale).</p></sec><sec id="sec2.4"><title>Study outcomes</title><p id="p0045">Women were eligible for inclusion in this secondary analysis if they had a singleton pregnancy with known birth outcome, and samples collected within 6 prespecified gestational age bins: 16-&#x0003c;20, 20-&#x0003c;24, 24-&#x0003c;28, 28-&#x0003c;32, 32-&#x0003c;36, 36-&#x0003c;37 weeks of gestation. The primary exposure was biomarker levels and the primary outcome was PTB (so samples were not tested &#x0003e;36 weeks of completed gestation). PTB was defined as delivery &#x0003c;37 weeks of gestation (ultrasound dated), SGA was defined using INTERGROWTH standards,<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> and stillbirth defined as intrauterine fetal demise &#x02265;20 weeks of gestation.</p></sec><sec id="sec2.5"><title>Enzyme-linked immunosorbent assays</title><p id="p0050">EDTA plasma samples were collected and stored at &#x02212;80&#x000b0;C prior to testing. Samples were tested in Uganda using commercially available enzyme-linked immunosorbent assays (Duosets, R&#x00026;D Systems, Minneapolis, MN) with the following ranges, dilution factors, and intraassay coefficients of variation: Ang-1 (313-20,000 pg/mL, 1:10, 5.6%); Ang-2 (93.8-6000 pg/mL, 1:20, 6.1%); sEng (250-16,000 pg/mL, 1:20, 7.4%); sFlt-1 (250-16,000 pg/mL, 1:5, 11.9%); PlGF (63.0-4000 pg/mL, 1:5, 8.1%), and VEGF (31-2000 pg/mL, 1:2). All testing was performed blinded to group and outcome.</p></sec><sec id="sec2.6"><title>Statistical analysis</title><p id="p0055">Statistical analysis was performed using STATA v14 (StataCorp, College Station, TX), R v3.2.1<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> (R Foundation for Statistical Computing), and GraphPad Prism v6 (GraphPad Software Inc, La Jolla, CA) software. Descriptive statistics were calculated as n (%) and median (interquartile range). The &#x003c7;<sup>2</sup> and Fisher exact tests were used to compare categorical variables. Linear regression was used to assess whether biomarker levels changed over pregnancy. To assess the effect of gestational age on angiogenic factor concentrations between birth outcome groups, we used the lme4<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> package in R<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> to construct linear mixed effects (LME) models with random intercept and random slope, adapting the approach employed by Romero et&#x000a0;al.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> For each biomarker and outcome, we constructed a null model with 4 fixed effects: the linear effect of gestational age, maternal age, body mass index (BMI), and gravidity. To make the intercept meaningful, the gestational age variable was shifted such that the lowest gestational age in our data set (the baseline samples) would be the intercept&#x02019;s x-value. We also included the interaction between gestational age and treatment arm, to control for the possibility that the treatment affected the biomarker&#x02019;s rate of change. Treatment arm was omitted as a main effect to constrain the&#x000a0;groups to have the same intercept, as&#x000a0;baseline differences between the (randomly allocated) groups would have been due to chance. In 2 additional models, we added the birth outcome as a fixed effect: an additive, no-interaction model and an interaction model. Both models were the same as the null but also included outcome as a main effect; and the interaction model further included the interaction between outcome and gestational age. For none of the biomarkers or birth outcomes did the interaction term significantly improve the model fit (<italic>P</italic> &#x0003e; .05 for all). Therefore, the data favor the more parsimonious additive models. For models in which the groups had different intercepts, the fitted lines did not significantly converge or diverge over time. For random effects, all models included a by-participant intercept and by-participant slope for the effect of gestational age. The biomarker levels were transformed using the natural logarithm to stabilize their variance. Residual plots did not show any apparent deviation from homoscedasticity or normality. Statistical significance was assessed using likelihood ratio (LR) tests, which compared in a stepwise fashion the null model, the additive model, and the interaction model. As the PlGF values vary quadratically over time, we added a quadratic interaction term to the model, which significantly improved the model fit [LR test, &#x003c7;<sup>2</sup>(1)&#x000a0;= 157.15, <italic>P</italic> &#x0003c; .0001].</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Description of the study population</title><p id="p0060">A total of 1115 plasma samples were evaluated from 326 women and adolescents (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). The demographic characteristics of the study population are presented in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. The median age of women was 30 years with a median BMI at enrollment of 21.4 kg/m<sup>2</sup>. The majority of participants (n&#x000a0;= 271, 83%) were multigravida. None of the participants were diagnosed with chronic hypertension, preeclampsia, or eclampsia during the study period. Adverse birth outcomes in the cohort were common with 18.1% (n&#x000a0;= 59) of participants having a&#x000a0;low-birthweight infant (compared to a&#x000a0;national estimate of 12%<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref>), 16.9% (n&#x000a0;= 55) spontaneous PTB, 25.6% (n&#x000a0;=&#x000a0;81) SGA, and 2.8% (n&#x000a0;= 9) stillborn. The median gestational age of stillbirth deliveries was 31 weeks of gestation. Cause of fetal demise was not ascertained. Malaria infection status and birth outcomes did not differ between participants receiving lopinavir/ritonavir compared to&#x000a0;those receiving efavirenz (<xref rid="tblS1" ref-type="table">Supplemental Table&#x000a0;1</xref>).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Flow chart of maternal plasma samples processed by gestational age</p><p><italic>ART</italic>, antiretroviral therapy; <italic>EFV</italic>, efavirenz; <italic>LPV/r</italic>, lopinavir/ritonavir.</p><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Descriptive characteristics of study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Cohort, n&#x000a0;= 326</th></tr></thead><tbody><tr><td>Demographics</td><td/></tr><tr><td>Age, y</td><td>30 (26&#x02013;33)</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>21.4 (19.9&#x02013;23.0)</td></tr><tr><td>Socioeconomic status, tertile</td><td/></tr><tr><td>&#x000a0;1</td><td>111 (35.9)</td></tr><tr><td>&#x000a0;2</td><td>135 (43.7)</td></tr><tr><td>&#x000a0;3</td><td>63 (20.4)</td></tr><tr><td>Gestational age at enrollment, wk</td><td>23.6 (19.6&#x02013;27.9)</td></tr><tr><td>Previous pregnancies</td><td/></tr><tr><td>&#x000a0;0</td><td>20 (6.1)</td></tr><tr><td>&#x000a0;1</td><td>35 (10.7)</td></tr><tr><td>&#x000a0;2</td><td>271 (83.1)</td></tr><tr><td>Laboratory characteristics</td><td/></tr><tr><td>Hemoglobin level, g/dL</td><td>11.0 (10.2&#x02013;11.8)</td></tr><tr><td>White blood cell count, cells/mm<sup>3</sup></td><td>5050 (4200&#x02013;6200)</td></tr><tr><td>Platelet count,&#x000a0;&#x000d7;10<sup>9</sup>/L</td><td>210 (173&#x02013;252)</td></tr><tr><td>CD4<sup>+</sup> T-cell count, cells/mm<sup>3</sup></td><td>369 (271&#x02013;504)</td></tr><tr><td>HIV RNA load, log<sub>10</sub> copies/mL</td><td>4.2 (3.9&#x02013;4.8)</td></tr><tr><td>Delivery characteristics</td><td/></tr><tr><td>Gestational age delivery, wk</td><td>38 (37&#x02013;40)</td></tr><tr><td>Birthweight, kg</td><td>2890 (2670&#x02013;3230)</td></tr><tr><td>Preterm birth</td><td>55 (16.9)</td></tr><tr><td>Small for gestational age</td><td>81 (25.6)</td></tr><tr><td>Stillbirth</td><td>9 (2.8)</td></tr><tr><td>Placental malaria<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td>24 (8.7)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Continuous variables expressed as median (interquartile range), categorical variables expressed as n (%).</p></fn><fn id="tspara0020"><p><italic>BMI</italic>, body mass index.</p></fn><fn id="tspara0025"><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0035">Defined by positive finding of placental blood smear or polymerase chain reaction.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.2"><title>Longitudinal changes in angiogenic factors over pregnancy</title><p id="p0065">There were no differences in angiogenic proteins by trial arm (<xref rid="figS1" ref-type="fig">Supplemental Figure&#x000a0;1</xref>), so subsequent analysis was conducted using the combined cohort. We plotted the longitudinal kinetics of angiogenic factors over pregnancy and observed declining levels of Ang-2 across gestation, and increasing levels PlGF, sFlt-1, and sEng (<italic>P</italic> &#x0003c; .0001 for all) (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). There were no differences in circulating Ang-1 levels across gestation. Median plasma Ang-2 decreased from 6.6 ng/mL at 16-20 weeks to 2.5 ng/mL by 37 weeks of gestation. Median levels of sEng increased from 9.1-14.7 ng/mL and sFlt-1 increased from 1.9-6.4 ng/mL from 16-20 and 37 weeks of gestation (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). PlGF levels were 0.24 ng/mL at 16-20 weeks, peaked at 0.84 ng/mL at 28-32 weeks, and declined to 0.40 ng/mL by 37 weeks of gestation (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>). VEGF-A levels were largely undetectable&#x000a0;with 87% of samples having concentrations below the bottom standard of 31.3&#x000a0;pg/mL.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Angiogenic factors in HIV infected study participants receiving antiretroviral therapy</p><p>Scatter plot of plasma levels of angiogenic factors plotted according to gestational age of sample collection: <bold>A</bold>, placental growth factor (PlGF); <bold>B</bold>, soluble fms-like tyrosine kinase (sFlt)-1; <bold>C</bold>, soluble endoglin (sEng); <bold>D</bold>, angiopoietin (Ang)-2; and <bold>E</bold>, Ang-1. Line indicates best fit line with 95% confidence intervals.</p><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec3.3"><title>Relationship between angiogenic factors and immune status</title><p id="p0070">To determine whether angiogenic factors were associated with maternal health or immune status, we conducted nonparametric bivariate correlations comparing angiogenic proteins and enrollment laboratory tests. There were no differences between angiogenic proteins measured in the first gestational age bin (16-&#x0003c;20 weeks of gestation) and enrollment hemoglobin, platelet count, viral load, or CD4 count (<italic>P</italic> &#x0003e; .05 for all).</p></sec><sec id="sec3.4"><title>Relationship between angiogenic factors and birth outcomes</title><p id="p0075">LME modeling evaluated the longitudinal changes in angiogenic factor concentrations between birth outcome groups. The&#x000a0;models adjusted for gestational age at&#x000a0;venipuncture, maternal age, BMI, gravidity, and the interaction between treatment arm and gestational age (<xref rid="tbl2" ref-type="table">Tables&#x000a0;2</xref> and <xref rid="tbl3" ref-type="table">3</xref>, and <xref rid="tblS2" ref-type="table">Table S2</xref>, <xref rid="tblS3" ref-type="table">Table S3</xref>, <xref rid="tblS4" ref-type="table">Table S4</xref>). Two angiogenic factors&#x02013;sEng and PlGF&#x02013;were associated with adverse birth outcomes. Significantly higher concentrations of sEng throughout gestation were found in study participants destined to deliver preterm [LR test, &#x003c7;<sup>2</sup>(1)&#x000a0;= 12.28, <italic>P</italic> &#x0003c; .0005] (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>, A) and in those destined to have stillbirths [&#x003c7;<sup>2</sup>(1)&#x000a0;= 5.67, <italic>P</italic> &#x0003c; .02] (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>, B, and <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). By contrast, significantly lower concentrations of PlGF throughout gestation were found in those destined to have SGA births [&#x003c7;<sup>2</sup>(1)&#x000a0;= 7.89, <italic>P</italic> &#x0003c; .005] (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>, C) and in those destined to have stillbirths [&#x003c7;<sup>2</sup>(1)&#x000a0;= 21.59, <italic>P</italic> &#x0003c; .0001] (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>, D, and <xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>). To show the natural variability of biomarkers over gestation among individual participants, we generated trellis plots for a random subset of participants with the fitted regression line from the LME model conditional on fixed effects only (<xref rid="figS2" ref-type="fig">Supplemental Figure&#x000a0;2</xref>, <xref rid="figS3" ref-type="fig">Supplemental Figure&#x000a0;3</xref>, <xref rid="figS4" ref-type="fig">Supplemental Figure&#x000a0;4</xref>, <xref rid="figS5" ref-type="fig">Supplemental Figure&#x000a0;5</xref>).<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Antiangiogenic shift is associated with adverse birth outcomes in women living with HIV receiving antiretroviral therapy</p><p>Individual data points colored by birth outcome. Overlaid regression lines are from linear mixed effects models, fitted for subject with average values (conditional on fixed effects only).</p><p><italic>AGA</italic>, appropriate for gestational age; <italic>PlGF</italic>, placental growth factor; <italic>PTB</italic>, preterm birth; <italic>sEng</italic>, soluble endoglin; <italic>SGA</italic>, small for gestational age.</p><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></caption><graphic xlink:href="gr3"/></fig><table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>Linear mixed effect modelling of longitudinal changes in soluble endoglin and adverse birth outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Preterm birth<hr/></th><th colspan="2">Stillbirth<hr/></th></tr><tr><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th></tr></thead><tbody><tr><td>Fixed terms</td><td/><td/><td/><td/></tr><tr><td>(Intercept)</td><td>2.13733</td><td>0.1760</td><td>2.12762</td><td>0.1788</td></tr><tr><td>Birth outcome</td><td>0.16745</td><td>0.0475</td><td>0.26459</td><td>0.1110</td></tr><tr><td>Gestational age (shifted)</td><td>0.04093</td><td>0.0030</td><td>0.04064</td><td>0.0030</td></tr><tr><td>Maternal age</td><td>&#x02013;0.00102</td><td>0.0047</td><td>&#x02013;0.00154</td><td>0.0048</td></tr><tr><td>Enrollment BMI</td><td>&#x02013;0.00455</td><td>0.0063</td><td>&#x02013;0.00297</td><td>0.0064</td></tr><tr><td>Gravidity</td><td>&#x02013;0.01270</td><td>0.0109</td><td>&#x02013;0.01047</td><td>0.0111</td></tr><tr><td>Gestational age: treatment arm interaction</td><td>&#x02013;0.00507</td><td>0.0025</td><td>&#x02013;0.00471</td><td>0.0026</td></tr><tr><td>No. of subjects</td><td colspan="2">320</td><td colspan="2">320</td></tr><tr><td>Observations</td><td colspan="2">1085</td><td colspan="2">1085</td></tr><tr><td>LR test against null model</td><td colspan="2">&#x003c7;<sup>2</sup>(1)&#x000a0;= 12.282, <italic>P</italic> &#x0003c; .0005</td><td colspan="2">&#x003c7;<sup>2</sup>(1)&#x000a0;= 5.6717, <italic>P</italic> &#x0003c; .02</td></tr></tbody></table><table-wrap-foot><fn id="tspara0035"><p>Linear mixed effect modelling evaluated longitudinal changes in angiogenic factor concentrations between birth outcome groups. Models adjusted for gestational age at venipuncture, maternal age, BMI, gravidity, and interaction between treatment arm and gestational age.</p></fn><fn id="tspara0040"><p><italic>BMI</italic>, body mass index; <italic>LR</italic>, likelihood ratio.</p></fn><fn id="tspara0045"><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table&#x000a0;3</label><caption><p>Linear mixed effect modelling longitudinal changes in placental growth factor and adverse birth outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Small for gestational age<hr/></th><th colspan="2">Stillbirth<hr/></th></tr><tr><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th></tr></thead><tbody><tr><td>Fixed terms</td><td/><td/><td/><td/></tr><tr><td>(Intercept)</td><td>&#x02013;3.03817</td><td>0.6134</td><td>&#x02013;3.14340</td><td>0.5889</td></tr><tr><td>Birth outcome</td><td>&#x02013;0.38094</td><td>0.1357</td><td>&#x02013;1.66380</td><td>0.3520</td></tr><tr><td>Gestational age (shifted)</td><td>0.36286</td><td>0.0264</td><td>0.36828</td><td>0.0259</td></tr><tr><td>Gestational age (shifted) squared</td><td>&#x02013;0.01379</td><td>0.0010</td><td>&#x02013;0.01405</td><td>0.0010</td></tr><tr><td>Maternal age</td><td>0.01062</td><td>0.0163</td><td>0.00881</td><td>0.0156</td></tr><tr><td>Enrollment BMI</td><td>&#x02013;0.00981</td><td>0.0218</td><td>&#x02013;0.00876</td><td>0.0208</td></tr><tr><td>Gravidity</td><td>0.06139</td><td>0.0379</td><td>0.07530</td><td>0.0359</td></tr><tr><td>Gestational age: treatment arm interaction</td><td>&#x02013;0.00384</td><td>0.0087</td><td>&#x02013;0.00421</td><td>0.0085</td></tr><tr><td>No. of subjects</td><td colspan="2">311</td><td colspan="2">320</td></tr><tr><td>Observations</td><td colspan="2">1080</td><td colspan="2">1104</td></tr><tr><td>LR test against null model</td><td colspan="2">&#x003c7;<sup>2</sup>(1)&#x000a0;= 7.892, <italic>P</italic> &#x0003c; .005</td><td colspan="2">&#x003c7;<sup>2</sup>(1)&#x000a0;= 21.595, <italic>P</italic> &#x0003c; .0001</td></tr></tbody></table><table-wrap-foot><fn id="tspara0055"><p>Linear mixed effect modelling evaluated longitudinal changes in angiogenic factor concentrations between birth outcome groups. Models adjusted for gestational age at venipuncture, maternal age, BMI, gravidity, and interaction between treatment arm and gestational age.</p></fn><fn id="tspara0060"><p><italic>BMI</italic>, body mass index; <italic>LR</italic>, likelihood ratio.</p></fn><fn id="tspara0065"><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec4"><title>Comment</title><sec id="sec4.1"><title>Principal findings of the study</title><p id="p0080">Angiogenic processes in the placenta are critical regulators of fetal growth, but there are limited data documenting these processes in low-resource settings where maternal infections are common. In this study we assessed longitudinal concentrations in angiogenic proteins in HIV-infected pregnant women and adolescents started on ART. There were no differences in angiogenic factors by treatment arm. All proteins except Ang-1 and VEGF-A were dynamically regulated over gestation. Ang-2 levels declined, while sFlt-1 and sEng increased over gestation, and PlGF increased up to 32 weeks of gestation and&#x000a0;then declined. Altered expression of&#x000a0;angiogenic factors was associated with&#x000a0;spontaneous PTB, SGA, and stillbirth. These data suggest an early shift toward an antiangiogenic state is a common pathway associated with adverse birth outcomes in WLHIV, consistent with data from HIV-uninfected women.<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref> Placental malaria was uncommon in this study due to the&#x000a0;distribution of insecticide-treated bed nets and daily prophylaxis with trimethoprim-sulfamethoxazole.</p></sec><sec id="sec4.2"><title>Comparison with previous studies</title><p id="p0085">We evaluated 1115 plasma samples collected from 326 women and adolescents between 16-&#x0003c;37 weeks of gestation. We compared our findings directly to results from women enrolled in a clinical trial receiving calcium supplementation in pregnancy with longitudinal assessment of sFlt-1, PlGF and VEGF,<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> and sEng<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> between 8-42 weeks of gestation.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Both sFlt-1 and sEng levels increased over pregnancy starting at 24-28 weeks of gestation. While levels of sFlt-1 increased 3-fold over the third trimester, levels of sEng reached a plateau by 32-26 weeks of gestation. PlGF levels increased in early pregnancy, peaked between 28-32 weeks of gestation, and declined. Our results were consistent with those from the calcium trial suggesting temporal regulation of angiogenic factors is tightly controlled across pregnancy. In both studies, VEGF was measured but was undetectable in the majority of samples.</p><p id="p0090">Despite their important regulatory role in placental vascular development, data on Ang kinetics in pregnancy are limited. Our observations are consistent with a report of decreased placental Ang-2 messenger RNA over pregnancy.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Placental expression of Ang-2 messenger RNA is strongly correlated with circulating Ang-2 protein levels.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Our results are further supported by a study examining plasma Ang levels between 10-37 weeks of gestation where Ang-2 levels decreased and Ang-1 remained the same across gestation.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> Collectively these data demonstrate the Ang-Tie-2 axis is dynamically regulated over pregnancy.</p><p id="p0095">There are limited data on the impact of maternal HIV infection on expression of angiogenic factors. Lower PlGF levels have been reported in pregnant WLHIV in South Africa<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref>; however, the sample size was small (n&#x000a0;= 27 HIV-uninfected, n&#x000a0;= 31 WLHIV), and samples were collected a week later in WLHIV. Other studies examining angiogenic factors in nonpregnant individuals infected with HIV have shown increases in the Ang-2:Ang-1 ratio associated with acute HIV infection, and decreased Ang-1 in chronic disease.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> In HIV-infected Kenyan women with advanced infection, Ang-2 levels decreased and Ang-1 levels increased following the initiation of ART.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> On a cellular level, HIV-infected cells release transactivator of transcription, which accumulates on and&#x000a0;is taken up by endothelial cells where&#x000a0;it acts in synergy with VEGF-A to modify the cytoskeletal structure of endothelium.<xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref></p><p id="p0100">There have been a number of studies investigating the relationship between placental angiogenesis, vascular remodeling, and stillbirth. In a study of 22 unexplained stillbirths and 44 age-matched live-born controls, stillbirth was associated with increased placental microvascular density, vasculopathy, and&#x000a0;increased vascular permeability,<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> suggesting increased vascular remodeling in terminal stillbirth placentae. In contrast, in 1269 singleton women with samples collected between 30-34 weeks of gestation, a low PlGF/sFlt-1 ratio was associated with stillbirth.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Levels of sFlt-1 and sEng in the highest quartile of amniotic fluid were associated with increased odds of stillbirth in women with unexplained fetal death.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> In a longitudinal nested case-control study of women with a fetal death compared to those with an appropriate-for-gestational-age term delivery, the first trimester (weeks 7-11) was characterized by a proangiogenic phenotype (low sFlt-1, low sEng, high PlGF) and this shifted in favor of an antiangiogenic phenotype over the second and third trimester (between 23-41 weeks of gestation).<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Another cohort showed low sFlt-1 and PlGF levels in the first trimester were associated with spontaneous abortion.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Our data support and extend the hypothesis that an antiangiogenic state in the second and third trimester is associated with subsequent stillbirth with lower PlGF and higher sEng levels. As the placental vascular network undergoes continual growth and remodeling, it requires the coordinated regulation of angiogenic factors in a spatial, temporal, and quantitative manner. Additional studies are needed to assess how temporal changes in angiogenic factors during pregnancy relate to the vascular phenotype observed in the placenta at delivery.</p><p id="p0105">Beginning in the second trimester the&#x000a0;placenta undergoes a continuous process of sprouting angiogenesis, intercalated growth, and intussusception. This remodeling allows for increased placental volume and surface area for nutrient exchange to support the rapidly growing fetus. Dysregulation of the pathways that mediate these processes midpregnancy may result in preterm delivery or fetal growth restriction if the placenta cannot support this rapid growth. Relative increases in sEng levels across gestation were associated with spontaneous PTB in this cohort, supporting the hypothesis that an antiangiogenic environment can contribute to premature birth.<xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref> Likewise, reduced PlGF across gestation was associated with SGA, consistent with previous literature linking PlGF to placental and fetal growth and development.<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib50" ref-type="bibr">50</xref></p></sec><sec id="sec4.3"><title>Strengths and weaknesses</title><p id="p0110">This study has several strengths including ultrasound-confirmed gestational dating and frequent blood sampling. Despite routine clinical monitoring over pregnancy including monthly blood pressure and proteinuria assessments, no women in this cohort developed preeclampsia. This study is the first to present detailed kinetics data from a low-resource setting where the burden of disease is greatest, but for which we have the least amount of data. The lack of an HIV-uninfected comparison group in this study is a limitation that prevents us from discussing the generalizability of the findings or the relative impact of maternal HIV infection. While we did not observe any changes in angiogenic factor expression by treatment arm, CD4 count, or HIV-1 RNA viral load at enrollment, additional studies are needed to delineate the role of HIV-1 infection on the expression of angiogenic factors to determine whether infection itself modifies also the risk of adverse birth outcomes through dysregulated angiogenesis.</p></sec><sec id="sec4.4"><title>Research and clinical implications</title><p id="p0115">This study was conducted in a rural area of southeastern Uganda where the low incidence of preeclampsia is consistent with clinical reports from the region. While the reason for this is unknown, we speculate that a relative absence of risk factors for preeclampsia, including nulliparity, coupled with lower weight gain over gestation contributed to a lower risk of preeclampsia.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> The median weekly weight gain in the study was 0.2 kg with nearly 20% of women gaining no weight over the study period.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> Additional studies are needed to validate these findings in HIV-infected women and in populations where preeclampsia is more common to ascertain the generalizability of these findings, and whether early assessment of angiogenic markers may have utility in identifying high-risk pregnancies.</p></sec><sec id="sec4.5"><title>Conclusions</title><p id="p0120">Early changes in angiogenic proteins may have predictive utility in identifying women at risk of adverse birth outcomes in WLHIV receiving ART. While these findings need to be prospectively validated, early identification of women at increased risk of adverse birth outcomes may facilitate enhanced monitoring and referral to health care facilities equipped to manage high-risk pregnancies (<xref rid="mmc1" ref-type="supplementary-material">Video</xref>).</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="book" id="sref1"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><chapter-title>Global summary of the AIDS epidemic</chapter-title><year>2015</year><publisher-name>WHO-HIV Department</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>E.</given-names></name><name><surname>Mohammadi</surname><given-names>H.</given-names></name><name><surname>Loutfy</surname><given-names>M.R.</given-names></name></person-group><article-title>HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction</article-title><source>J&#x000a0;Infect Dis</source><volume>211</volume><year>2015</year><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">25030058</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.Y.</given-names></name><name><surname>Ribaudo</surname><given-names>H.J.</given-names></name><name><surname>Souda</surname><given-names>S.</given-names></name></person-group><article-title>Highly&#x000a0;active antiretroviral therapy and adverse&#x000a0;birth outcomes among HIV-infected women in Botswana</article-title><source>J&#x000a0;Infect Dis</source><volume>206</volume><year>2012</year><fpage>1695</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">23066160</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>E.S.</given-names></name><name><surname>Hofer</surname><given-names>C.B.</given-names></name><name><surname>Costa</surname><given-names>T.T.</given-names></name></person-group><article-title>Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception</article-title><source>Sex Transm Infect</source><volume>85</volume><year>2009</year><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">18987014</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Ekouevi</surname><given-names>D.K.</given-names></name><name><surname>Coffie</surname><given-names>P.A.</given-names></name><name><surname>Becquet</surname><given-names>R.</given-names></name></person-group><article-title>Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire</article-title><source>AIDS</source><volume>22</volume><year>2008</year><fpage>1815</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">18753864</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Wimalasundera</surname><given-names>R.C.</given-names></name><name><surname>Larbalestier</surname><given-names>N.</given-names></name><name><surname>Smith</surname><given-names>J.H.</given-names></name></person-group><article-title>Pre-eclampsia, antiretroviral therapy, and&#x000a0;immune reconstitution</article-title><source>Lancet</source><volume>360</volume><year>2002</year><fpage>1152</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">12387967</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Townsend</surname><given-names>C.L.</given-names></name><name><surname>Cortina-Borja</surname><given-names>M.</given-names></name><name><surname>Peckham</surname><given-names>C.S.</given-names></name><name><surname>Tookey</surname><given-names>P.A.</given-names></name></person-group><article-title>Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland</article-title><source>AIDS</source><volume>21</volume><year>2007</year><fpage>1019</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">17457096</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Powis</surname><given-names>K.M.</given-names></name><name><surname>Kitch</surname><given-names>D.</given-names></name><name><surname>Ogwu</surname><given-names>A.</given-names></name></person-group><article-title>Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy</article-title><source>J&#x000a0;Infect Dis</source><volume>204</volume><year>2011</year><fpage>506</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">21791651</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Newell</surname><given-names>M.L.</given-names></name><name><surname>Bunders</surname><given-names>M.J.</given-names></name></person-group><article-title>Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child</article-title><source>Curr Opin HIV AIDS</source><volume>8</volume><year>2013</year><fpage>504</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">23743789</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>S.</given-names></name><name><surname>Moren</surname><given-names>C.</given-names></name><name><surname>Lopez</surname><given-names>M.</given-names></name></person-group><article-title>Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn</article-title><source>AIDS</source><volume>26</volume><year>2012</year><fpage>419</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">22156962</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Zash</surname><given-names>R.</given-names></name><name><surname>Jacobson</surname><given-names>D.L.</given-names></name><name><surname>Diseko</surname><given-names>M.</given-names></name></person-group><article-title>Comparative safety of antiretroviral treatment regimens in pregnancy</article-title><source>JAMA Pediatr</source><volume>171</volume><year>2017</year><fpage>e172222</fpage><pub-id pub-id-type="pmid">28783807</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Nattabi</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Thompson</surname><given-names>S.C.</given-names></name><name><surname>Orach</surname><given-names>C.G.</given-names></name><name><surname>Earnest</surname><given-names>J.</given-names></name></person-group><article-title>A&#x000a0;systematic review of factors influencing fertility desires and intentions among people living with HIV/AIDS: implications for policy and service delivery</article-title><source>AIDS Behav</source><volume>13</volume><year>2009</year><fpage>949</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">19330443</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Kalk</surname><given-names>E.</given-names></name><name><surname>Schubert</surname><given-names>P.</given-names></name><name><surname>Bettinger</surname><given-names>J.A.</given-names></name></person-group><article-title>Placental pathology in HIV infection at term: a comparison with HIV-uninfected women</article-title><source>Trop Med Int Health</source><volume>22</volume><year>2017</year><fpage>604</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">28214384</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Geva</surname><given-names>E.</given-names></name><name><surname>Ginzinger</surname><given-names>D.G.</given-names></name><name><surname>Zaloudek</surname><given-names>C.J.</given-names></name><name><surname>Moore</surname><given-names>D.H.</given-names></name><name><surname>Byrne</surname><given-names>A.</given-names></name><name><surname>Jaffe</surname><given-names>R.B.</given-names></name></person-group><article-title>Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-a, angiopoietin-1, and angiopoietin-2</article-title><source>J&#x000a0;Clin Endocrinol Metab</source><volume>87</volume><year>2002</year><fpage>4213</fpage><lpage>4224</lpage><pub-id pub-id-type="pmid">12213874</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Charnock-Jones</surname><given-names>D.S.</given-names></name><name><surname>Kaufmann</surname><given-names>P.</given-names></name><name><surname>Mayhew</surname><given-names>T.M.</given-names></name></person-group><article-title>Aspects of human fetoplacental vasculogenesis and angiogenesis, I: molecular regulation</article-title><source>Placenta</source><volume>25</volume><year>2004</year><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">14972443</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>R.J.</given-names></name><name><surname>Maynard</surname><given-names>S.E.</given-names></name><name><surname>Qian</surname><given-names>C.</given-names></name></person-group><article-title>Circulating angiogenic factors and the risk of preeclampsia</article-title><source>N&#x000a0;Engl J Med</source><volume>350</volume><year>2004</year><fpage>672</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">14764923</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>McMaster</surname><given-names>M.</given-names></name><name><surname>Woo</surname><given-names>K.</given-names></name></person-group><article-title>Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome</article-title><source>Am J Pathol</source><volume>160</volume><year>2002</year><fpage>1405</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">11943725</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Hirokoshi</surname><given-names>K.</given-names></name><name><surname>Maeshima</surname><given-names>Y.</given-names></name><name><surname>Kobayashi</surname><given-names>K.</given-names></name></person-group><article-title>Elevated serum sFlt-1/Ang-2 ratio in women with preeclampsia</article-title><source>Nephron Clin Pract</source><volume>106</volume><year>2007</year><fpage>c43</fpage><lpage>c50</lpage><pub-id pub-id-type="pmid">17409768</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>R.J.</given-names></name><name><surname>Lam</surname><given-names>C.</given-names></name><name><surname>Qian</surname><given-names>C.</given-names></name></person-group><article-title>Soluble endoglin and other circulating antiangiogenic factors in preeclampsia</article-title><source>N&#x000a0;Engl J Med</source><volume>355</volume><year>2006</year><fpage>992</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">16957146</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Govender</surname><given-names>N.</given-names></name><name><surname>Naicker</surname><given-names>T.</given-names></name><name><surname>Rajakumar</surname><given-names>A.</given-names></name><name><surname>Moodley</surname><given-names>J.</given-names></name></person-group><article-title>Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><volume>170</volume><year>2013</year><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">23806447</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Chaiworapongsa</surname><given-names>T.</given-names></name><name><surname>Romero</surname><given-names>R.</given-names></name><name><surname>Korzeniewski</surname><given-names>S.J.</given-names></name></person-group><article-title>Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia</article-title><source>Am J Obstet Gynecol</source><volume>208</volume><year>2013</year><fpage>287.e1</fpage><lpage>287.e15</lpage><pub-id pub-id-type="pmid">23333542</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R.</given-names></name><name><surname>Nien</surname><given-names>J.K.</given-names></name><name><surname>Espinoza</surname><given-names>J.</given-names></name></person-group><article-title>A&#x000a0;longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate</article-title><source>J&#x000a0;Matern Fetal Neonatal Med</source><volume>21</volume><year>2008</year><fpage>9</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">18175241</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Chaiworapongsa</surname><given-names>T.</given-names></name><name><surname>Romero</surname><given-names>R.</given-names></name><name><surname>Kusanovic</surname><given-names>J.P.</given-names></name></person-group><article-title>Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations</article-title><source>Ultrasound Obstet Gynecol</source><volume>35</volume><year>2010</year><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">20101637</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Easter</surname><given-names>S.R.</given-names></name><name><surname>Cantonwine</surname><given-names>D.E.</given-names></name><name><surname>Zera</surname><given-names>C.A.</given-names></name><name><surname>Lim</surname><given-names>K.-H.</given-names></name><name><surname>Parry</surname><given-names>S.I.</given-names></name><name><surname>McElrath</surname><given-names>T.F.</given-names></name></person-group><article-title>Urinary tract infection during pregnancy, angiogenic factor profiles, and risk of preeclampsia</article-title><source>Am J Obstet Gynecol</source><volume>214</volume><year>2016</year><fpage>387.e1</fpage><lpage>387.e7</lpage><pub-id pub-id-type="pmid">26450405</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Baltajian</surname><given-names>K.</given-names></name><name><surname>Bajracharya</surname><given-names>S.</given-names></name><name><surname>Salahuddin</surname><given-names>S.</given-names></name></person-group><article-title>Sequential plasma angiogenic factors levels in women with suspected preeclampsia</article-title><source>Am J Obstet Gynecol</source><volume>215</volume><year>2016</year><fpage>89.e1</fpage><lpage>89.e10</lpage><pub-id pub-id-type="pmid">26827880</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Pearl</surname><given-names>M.</given-names></name><name><surname>DeLorenze</surname><given-names>G.N.</given-names></name></person-group><article-title>Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors</article-title><source>Am J Obstet Gynecol</source><volume>215</volume><year>2016</year><fpage>359.e1</fpage><lpage>359.e9</lpage><pub-id pub-id-type="pmid">27073062</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Holme</surname><given-names>A.M.</given-names></name><name><surname>Roland</surname><given-names>M.C.</given-names></name><name><surname>Henriksen</surname><given-names>T.</given-names></name><name><surname>Michelsen</surname><given-names>T.M.</given-names></name></person-group><article-title>In&#x000a0;vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies</article-title><source>Am J Obstet Gynecol</source><volume>215</volume><year>2016</year><fpage>782.e1</fpage><lpage>782.e9</lpage><pub-id pub-id-type="pmid">27503620</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.Y.</given-names></name><name><surname>Buyon</surname><given-names>J.P.</given-names></name><name><surname>Guerra</surname><given-names>M.M.</given-names></name></person-group><article-title>Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study</article-title><source>Am J Obstet Gynecol</source><volume>214</volume><year>2016</year><fpage>108.e1</fpage><lpage>108.e14</lpage><pub-id pub-id-type="pmid">26432463</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tasevski</surname><given-names>V.</given-names></name><name><surname>Wallace</surname><given-names>E.M.</given-names></name><name><surname>Gallery</surname><given-names>E.D.</given-names></name><name><surname>Morris</surname><given-names>J.M.</given-names></name></person-group><article-title>Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency</article-title><source>BJOG</source><volume>114</volume><year>2007</year><fpage>1427</fpage><lpage>1431</lpage><pub-id pub-id-type="pmid">17949380</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>R.N.</given-names></name><name><surname>Grimwood</surname><given-names>J.</given-names></name><name><surname>Taylor</surname><given-names>R.S.</given-names></name><name><surname>McMaster</surname><given-names>M.T.</given-names></name><name><surname>Fisher</surname><given-names>S.J.</given-names></name><name><surname>North</surname><given-names>R.A.</given-names></name></person-group><article-title>Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies</article-title><source>Am J Obstet Gynecol</source><volume>188</volume><year>2003</year><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">12548214</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Mijal</surname><given-names>R.S.</given-names></name><name><surname>Holzman</surname><given-names>C.B.</given-names></name><name><surname>Rana</surname><given-names>S.</given-names></name><name><surname>Karumanchi</surname><given-names>S.A.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Sikorskii</surname><given-names>A.</given-names></name></person-group><article-title>Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery</article-title><source>J&#x000a0;Matern Fetal Neonatal Med</source><volume>25</volume><year>2012</year><fpage>1135</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">21939291</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>R.</given-names></name><name><surname>Chaiworapongsa</surname><given-names>T.</given-names></name><name><surname>Erez</surname><given-names>O.</given-names></name></person-group><article-title>An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study</article-title><source>J&#x000a0;Matern Fetal Neonatal Med</source><volume>23</volume><year>2010</year><fpage>1384</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">20459337</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>L.B.</given-names></name><name><surname>Dechend</surname><given-names>R.</given-names></name><name><surname>Karumanchi</surname><given-names>S.A.</given-names></name></person-group><article-title>Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study</article-title><source>Am J Obstet Gynecol</source><volume>215</volume><year>2016</year><fpage>594.e1</fpage><lpage>594.e11</lpage><pub-id pub-id-type="pmid">27287686</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Korzeniewski</surname><given-names>S.J.</given-names></name><name><surname>Romero</surname><given-names>R.</given-names></name><name><surname>Chaiworapongsa</surname><given-names>T.</given-names></name></person-group><article-title>Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study</article-title><source>Am J Obstet Gynecol</source><volume>214</volume><year>2016</year><fpage>629.e1</fpage><lpage>629.e17</lpage><pub-id pub-id-type="pmid">26688491</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Redman</surname><given-names>C.W.G.</given-names></name><name><surname>Staff</surname><given-names>A.C.</given-names></name></person-group><article-title>Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity</article-title><source>Am J Obstet Gynecol</source><volume>213</volume><year>2015</year><fpage>S9.e1</fpage><lpage>S9.e4</lpage><pub-id pub-id-type="pmid">26428507</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>S.J.</given-names></name></person-group><article-title>Why is placentation abnormal in preeclampsia?</article-title><source>Am J Obstet Gynecol</source><volume>213</volume><year>2015</year><fpage>S115</fpage><lpage>S122</lpage><pub-id pub-id-type="pmid">26428489</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Yancopoulos</surname><given-names>G.D.</given-names></name><name><surname>Davis</surname><given-names>S.</given-names></name><name><surname>Gale</surname><given-names>N.W.</given-names></name><name><surname>Rudge</surname><given-names>J.S.</given-names></name><name><surname>Wiegand</surname><given-names>S.J.</given-names></name><name><surname>Holash</surname><given-names>J.</given-names></name></person-group><article-title>Vascular-specific growth factors and blood vessel formation</article-title><source>Nature</source><volume>407</volume><year>2000</year><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">11001067</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Krauss</surname><given-names>T.</given-names></name><name><surname>Pauer</surname><given-names>H.U.</given-names></name><name><surname>Augustin</surname><given-names>H.G.</given-names></name></person-group><article-title>Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia</article-title><source>Hypertens Pregnancy</source><volume>23</volume><year>2004</year><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">15117604</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>R.L.</given-names></name><name><surname>Thomas</surname><given-names>K.A.</given-names></name></person-group><article-title>Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor</article-title><source>Proc Natl Acad Sci U S A</source><volume>90</volume><year>1993</year><fpage>10705</fpage><lpage>10709</lpage><pub-id pub-id-type="pmid">8248162</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>A.L.</given-names></name><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>Sotov</surname><given-names>V.</given-names></name><name><surname>Letarte</surname><given-names>M.</given-names></name></person-group><article-title>Review: the enigmatic role of endoglin in the placenta</article-title><source>Placenta</source><volume>35S</volume><year>2014</year><fpage>S93</fpage><lpage>S99</lpage></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Lebrin</surname><given-names>F.</given-names></name><name><surname>Maring</surname><given-names>J.A.</given-names></name></person-group><article-title>Endoglin is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><fpage>e86273</fpage><pub-id pub-id-type="pmid">24489709</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Natureeba</surname><given-names>P.</given-names></name><name><surname>Ades</surname><given-names>V.</given-names></name><name><surname>Luwedde</surname><given-names>F.</given-names></name></person-group><article-title>Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women</article-title><source>J&#x000a0;Infect Dis</source><volume>210</volume><year>2014</year><fpage>1938</fpage><lpage>1945</lpage><pub-id pub-id-type="pmid">24958908</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Young</surname><given-names>S.</given-names></name><name><surname>Murray</surname><given-names>K.</given-names></name><name><surname>Mwesigwa</surname><given-names>J.</given-names></name></person-group><article-title>Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e41934</fpage><pub-id pub-id-type="pmid">22879899</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>J.</given-names></name><name><surname>Cheikh Ismail</surname><given-names>L.</given-names></name><name><surname>Victora</surname><given-names>C.G.</given-names></name></person-group><article-title>International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the Intergrowth-21st Project</article-title><source>Lancet</source><volume>384</volume><year>2014</year><fpage>857</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">25209487</pub-id></element-citation></ref><ref id="bib45"><label>45</label><mixed-citation publication-type="other" id="sref45">R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2017. <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/" id="interref0010">http://www.R-project.org/</ext-link>.</mixed-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref45a"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>D.</given-names></name></person-group><article-title>Fitting linear mixed-effects models using lme4</article-title><source>J&#x000a0;Stat Software</source><volume>67</volume><year>2015</year><fpage>1</fpage><lpage>48</lpage></element-citation></ref><ref id="bib47"><label>47</label><mixed-citation publication-type="other" id="sref47">United Nations Children's Fund and World Health Organization. Low birthweight: country, regional and global estimates. UNICEF New York: 2004.</mixed-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Chaiworapongsa</surname><given-names>T.</given-names></name><name><surname>Romero</surname><given-names>R.</given-names></name><name><surname>Tarca</surname><given-names>A.</given-names></name></person-group><article-title>A&#x000a0;subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study</article-title><source>J&#x000a0;Matern Fetal Neonatal Med</source><volume>22</volume><year>2009</year><fpage>1122</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">19916710</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>C.R.</given-names></name><name><surname>Darling</surname><given-names>A.M.</given-names></name><name><surname>Conroy</surname><given-names>A.L.</given-names></name></person-group><article-title>Inflammatory and angiogenic factors at mid-pregnancy are associated with spontaneous preterm birth in a cohort of Tanzanian women</article-title><source>PLoS One</source><volume>10</volume><year>2015</year><fpage>e0134619</fpage><pub-id pub-id-type="pmid">26247200</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Darling</surname><given-names>A.M.</given-names></name><name><surname>McDonald</surname><given-names>C.R.</given-names></name><name><surname>Conroy</surname><given-names>A.L.</given-names></name></person-group><article-title>Angiogenic and inflammatory biomarkers in midpregnancy and small-for-gestational-age outcomes in Tanzania</article-title><source>Am J Obstet Gynecol</source><volume>211</volume><year>2014</year><fpage>509.e1</fpage><lpage>509.e8</lpage><pub-id pub-id-type="pmid">24881826</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Joffe</surname><given-names>G.M.</given-names></name><name><surname>Esterlitz</surname><given-names>J.R.</given-names></name><name><surname>Levine</surname><given-names>R.J.</given-names></name></person-group><article-title>The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in&#x000a0;healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) study group</article-title><source>Am J Obstet Gynecol</source><volume>179</volume><year>1998</year><fpage>1032</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">9790393</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Bolin</surname><given-names>M.</given-names></name><name><surname>Wiberg-Itzel</surname><given-names>E.</given-names></name><name><surname>Wikstr&#x000f6;m</surname><given-names>A.-K.</given-names></name></person-group><article-title>Angiopoietin-1/angiopoietin-2 ratio for prediction of preeclampsia</article-title><source>Am J Hypertens</source><volume>22</volume><year>2009</year><fpage>891</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">19478794</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Govender</surname><given-names>N.</given-names></name><name><surname>Naicker</surname><given-names>T.</given-names></name><name><surname>Moodley</surname><given-names>J.</given-names></name></person-group><article-title>Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia</article-title><source>Cardiovasc J Afr</source><volume>24</volume><year>2013</year><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">24217170</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>S.M.</given-names></name><name><surname>Rajwans</surname><given-names>N.</given-names></name><name><surname>Jaoko</surname><given-names>W.</given-names></name></person-group><article-title>Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression</article-title><source>AIDS</source><volume>27</volume><year>2013</year><fpage>1803</fpage><lpage>1813</lpage><pub-id pub-id-type="pmid">23807276</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>S.M.</given-names></name><name><surname>Rajwans</surname><given-names>N.</given-names></name><name><surname>Tapia</surname><given-names>K.A.</given-names></name></person-group><article-title>A&#x000a0;prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy</article-title><source>BMC Infect Dis</source><volume>13</volume><year>2013</year><fpage>263</fpage><pub-id pub-id-type="pmid">23734875</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Urbinati</surname><given-names>C.</given-names></name><name><surname>Nicoli</surname><given-names>S.</given-names></name><name><surname>Giacca</surname><given-names>M.</given-names></name></person-group><article-title>HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium</article-title><source>Blood</source><volume>114</volume><year>2009</year><fpage>3335</fpage><lpage>3342</lpage><pub-id pub-id-type="pmid">19661268</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Das</surname><given-names>J.R.</given-names></name><name><surname>Gutkind</surname><given-names>J.S.</given-names></name><name><surname>Ray</surname><given-names>P.E.</given-names></name></person-group><article-title>Circulating fibroblast growth factor-2, HIV-Tat, and vascular endothelial cell growth factor-A in HIV-infected children with renal disease activate Rho-A and Src in cultured renal endothelial cells</article-title><source>PLoS One</source><volume>11</volume><year>2016</year><fpage>e0153837</fpage><pub-id pub-id-type="pmid">27097314</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Plunkett</surname><given-names>B.A.</given-names></name><name><surname>Fitchev</surname><given-names>P.</given-names></name><name><surname>Doll</surname><given-names>J.A.</given-names></name></person-group><article-title>Decreased expression of pigment epithelium derived factor (PEDF), an inhibitor of angiogenesis, in placentas of unexplained stillbirths</article-title><source>Reprod Biol</source><volume>8</volume><year>2008</year><fpage>107</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">18677399</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Gavard</surname><given-names>J.A.</given-names></name></person-group><article-title>Gestational weight gain and maternal and neonatal outcomes in underweight pregnant women: a population-based historical cohort study</article-title><source>Matern Child Health J</source><volume>21</volume><year>2017</year><fpage>1203</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">28132170</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Koss</surname><given-names>C.A.</given-names></name><name><surname>Natureeba</surname><given-names>P.</given-names></name><name><surname>Plenty</surname><given-names>A.</given-names></name></person-group><article-title>Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy</article-title><source>J&#x000a0;Acquir Immune Defic Syndr (1999)</source><volume>67</volume><year>2014</year><fpage>128</fpage><lpage>135</lpage></element-citation></ref></ref-list><sec id="appsec1"><title>Appendix</title><p id="p0130"><fig id="figS1"><label>Supplemental Figure&#x000a0;1</label><caption><p>Longitudinal changes in angiogenic factors by treatment arm</p><p>Scatter plot of plasma levels of angiogenic factors plotted by treatment arm with nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART) in red and protease inhibitor (PI)-based ART in blue. Biomarkers plotted according to gestational age of sample collection: <bold>A</bold>,&#x000a0;placental growth factor (PlGF); <bold>B</bold>, soluble fms-like tyrosine kinase (sFlt)-1; <bold>C</bold>, soluble endoglin (sEng); <bold>D</bold>, angiopoietin (Ang)-2; and <bold>E</bold>, Ang-1. Line indicates best fit line with 95% confidence intervals.</p><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></caption><graphic xlink:href="fx1"/></fig><fig id="figS2"><label>Supplemental Figure&#x000a0;2</label><caption><p>Representative plots of soluble endoglin (sEng) levels over gestation in participants destined to have preterm or term delivery</p><p>Trellis plots of 60 randomly selected subjects (n&#x000a0;= 30 term, n&#x000a0;= 30 preterm). Solid line depicts fitted regression line from linear mixed effect model (conditional on fixed effects only).</p><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></caption><graphic xlink:href="fx2"/></fig><fig id="figS3"><label>Supplemental Figure&#x000a0;3</label><caption><p>Representative plots of soluble endoglin (sEng) levels over gestation in participants destined to have livebirth or stillbirth infant</p><p>Trellis plots of 18 randomly selected subjects (n&#x000a0;= 9 livebirth, n&#x000a0;= 9 stillbirth). Solid line depicts fitted regression line from linear mixed effect model (conditional on fixed effects only).</p><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></caption><graphic xlink:href="fx3"/></fig><fig id="figS4"><label>Supplemental Figure&#x000a0;4</label><caption><p>Representative plots of placental growth factor (PlGF) levels over gestation in participants destined to have small-for-gestational-age (SGA) or appropriate-for-gestational-age (AGA) infant</p><p>Trellis plots of 60 randomly selected subjects (n&#x000a0;= 30 AGA, n&#x000a0;= 30 SGA). Solid line depicts fitted regression line from linear mixed effect model (conditional on fixed effects only).</p><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></caption><graphic xlink:href="fx4"/></fig><fig id="figS5"><label>Supplemental Figure&#x000a0;5</label><caption><p>Representative plots of placental growth factor (PlGF) levels over gestation in women destined to have livebirth or stillbirth infant</p><p>Trellis plots of 18 randomly selected subjects (n&#x000a0;= 9 livebirth, n&#x000a0;= 9 stillbirth). Solid line depicts fitted regression line from linear mixed effect model (conditional on fixed effects only).</p><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></caption><graphic xlink:href="fx5"/></fig><table-wrap id="tblS1" position="anchor"><label>Table S1</label><caption><p>Descriptive characteristics of the study population by ART treatment arm</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Baseline Characteristic</th><th colspan="2">Treatment Arm<hr/></th><th rowspan="2"><italic>P</italic> Value</th></tr><tr><th>Efavirenz-Based ART, n=160</th><th>Lopinavir/ritonavir -Based ART, n=166</th></tr></thead><tbody><tr><td>Age (years)</td><td>30 [26, 33]</td><td>29.2 &#x000b1; 5.3</td><td>0.623</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>21.2 [19.6, 22.9]</td><td>21.6 [20.2, 23.2]</td><td>0.074</td></tr><tr><td>Socioeconomic status (tertile)</td><td/><td/><td>0.611</td></tr><tr><td>&#x000a0;1</td><td>54 (36.2)</td><td>57 (35.6)</td><td/></tr><tr><td>&#x000a0;2</td><td>68 (45.6)</td><td>67 (41.9)</td><td/></tr><tr><td>&#x000a0;3</td><td>27 (18.1)</td><td>36 (22.)</td><td/></tr><tr><td>Gestational age enrolment (weeks)</td><td>23.6 [19.7, 27.6]</td><td>23.5 [19.4, 27.0]</td><td>0.711</td></tr><tr><td>Previous pregnancies</td><td/><td/><td/></tr><tr><td>&#x000a0;0</td><td>13 (8.3)</td><td>7 (4.2)</td><td>0.275</td></tr><tr><td>&#x000a0;1</td><td>15 (9.6)</td><td>20 (12.1)</td><td/></tr><tr><td>&#x000a0;&#x02265;2</td><td>132 (82.2)</td><td>139 (83.6)</td><td/></tr><tr><td>Hemoglobin level (g/dL)</td><td>11.0 [10.2, 11.8]</td><td>11.1 [10.2, 11.7]</td><td>0.855</td></tr><tr><td>White blood cell count (cells/mm<sup>3</sup>)</td><td>4900 [4100, 6100]</td><td>5200 [4300, 6400]</td><td>0.134</td></tr><tr><td>Platelet count (x10<sup>9</sup>/L)</td><td>218.0 [177.5, 255.5]</td><td>201.0 [167.0, 239.5]</td><td>0.080</td></tr><tr><td>CD4+T-cell count (cells/mm<sup>3</sup>)</td><td>373.0 (269.3-497.8)</td><td>368.0 (280.5-507.5)</td><td>0.575</td></tr><tr><td>HIV RNA load (log<sub>10</sub>copies/mL)</td><td>4.286 [3.427, 4.837]</td><td>4.097 [3.328, 4.755]</td><td>0.468</td></tr><tr><td><bold>Outcome Characteristics</bold></td><td/><td/><td/></tr><tr><td>Gestational age delivery (weeks)</td><td>39 (37-40)</td><td>38 (37-39)</td><td>0.061</td></tr><tr><td>Birth weight (kg)</td><td>2910 (2680-3240)</td><td>2880 (2650-3210)</td><td>0.503</td></tr><tr><td>Preterm birth</td><td>24 (15.0)</td><td>31 (18.7)</td><td>0.376</td></tr><tr><td>Small-for-gestational age</td><td>44 (27.2)</td><td>37 (23.9)</td><td>0.502</td></tr><tr><td>Stillbirth</td><td>4 (2.5)</td><td>5 (3.0)</td><td>1.000</td></tr><tr><td>Placental malaria<xref rid="tblS1fn1" ref-type="table-fn">1</xref></td><td>14 (10.2)</td><td>10 (7.1)</td><td>0.363</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015e"><p>Continuous variables expressed as median (interquartile range), categorical variables expressed as n (%).</p></fn><fn id="tspara0065r"><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblS1fn1"><label>1</label><p id="ntpara0015w">Placental malaria defined by a positive finding of a placental blood smear or PCR.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tblS2" position="anchor"><label>Table S2</label><caption><p>Linear mixed effects models of angiogenic markers and preterm birth</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Ang-1<hr/></th><th colspan="2">Ang-2<hr/></th><th colspan="2">sFlt-1<hr/></th><th colspan="2">PlGF<hr/></th><th colspan="2">sEng<hr/></th></tr><tr><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th></tr></thead><tbody><tr><td><bold>Fixed Terms</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>(Intercept)</td><td>2.13479</td><td align="char">0.4445</td><td align="char">2.17519</td><td>0.3960</td><td align="char">&#x02212;0.43520</td><td align="char">0.5145</td><td align="char">&#x02212;3.26956</td><td align="char">0.6119</td><td align="char">2.13733</td><td align="char">0.1760</td></tr><tr><td>Preterm</td><td>0.13387</td><td align="char">0.1206</td><td align="char">&#x02212;0.15845</td><td>0.1068</td><td align="char">0.17902</td><td align="char">0.1499</td><td align="char">&#x02212;0.16196</td><td align="char">0.1617</td><td align="char">0.16745</td><td align="char">0.0475</td></tr><tr><td>Gestational age (shifted)</td><td>&#x02212;0.00844</td><td align="char">0.0064</td><td align="char">&#x02212;0.06347</td><td>0.0053</td><td align="char">0.15426</td><td align="char">0.0094</td><td align="char">0.36999</td><td align="char">0.0260</td><td align="char">0.04093</td><td align="char">0.0030</td></tr><tr><td>Gestational age (shifted) squared</td><td/><td/><td/><td/><td/><td/><td align="char">&#x02212;0.01407</td><td align="char">0.0010</td><td/><td/></tr><tr><td>Maternal age</td><td>&#x02212;0.00304</td><td align="char">0.0120</td><td align="char">&#x02212;0.01471</td><td>0.0109</td><td align="char">&#x02212;0.00375</td><td align="char">0.0132</td><td align="char">0.00646</td><td align="char">0.0162</td><td align="char">&#x02212;0.00102</td><td align="char">0.0047</td></tr><tr><td>Enrolment BMI</td><td>0.00297</td><td align="char">0.0161</td><td align="char">0.00655</td><td>0.0144</td><td align="char">&#x02212;0.02036</td><td align="char">0.0181</td><td align="char">&#x02212;0.00298</td><td align="char">0.0216</td><td align="char">&#x02212;0.00455</td><td align="char">0.0063</td></tr><tr><td>Gravidity</td><td>&#x02212;0.02431</td><td align="char">0.0277</td><td align="char">0.01920</td><td>0.0253</td><td align="char">&#x02212;0.02479</td><td align="char">0.0308</td><td align="char">0.08150</td><td align="char">0.0375</td><td align="char">&#x02212;0.01270</td><td align="char">0.0109</td></tr><tr><td>Gestational age: treatment arm interaction</td><td>0.00132</td><td align="char">0.0062</td><td align="char">&#x02212;0.00290</td><td>0.0063</td><td align="char">0.00437</td><td align="char">0.0058</td><td align="char">&#x02212;0.00402</td><td align="char">0.0086</td><td align="char">&#x02212;0.00507</td><td align="char">0.0025</td></tr><tr><td>Number of subjects</td><td colspan="2">320</td><td colspan="2">312</td><td colspan="2">320</td><td colspan="2">320</td><td colspan="2">320</td></tr><tr><td>Observations</td><td colspan="2">1104</td><td colspan="2">1049</td><td colspan="2">1104</td><td colspan="2">1104</td><td colspan="2">1085</td></tr><tr><td>LR Test against Null Model</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 1259, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 2.233, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 1.444, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 1.020, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 12.282, p &#x0003c; 0.0005*</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tblS3" position="anchor"><label>Table S3</label><caption><p>Linear mixed effects models of angiogenic markers and small-for-gestational age</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Ang-1<hr/></th><th colspan="2">Ang-2<hr/></th><th colspan="2">sFlt-1<hr/></th><th colspan="2">PlGF<hr/></th><th colspan="2">sEng<hr/></th></tr><tr><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th></tr></thead><tbody><tr><td><bold>Fixed Terms</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>(Intercept)</td><td align="char">2.14191</td><td align="char">0.4559</td><td align="char">2.13246</td><td align="char">0.4024</td><td align="char">&#x02212;0.39429</td><td align="char">0.5229</td><td align="char">&#x02212;3.03817</td><td align="char">0.6134</td><td align="char">2.12674</td><td align="char">0.1820</td></tr><tr><td>Stillbirth</td><td align="char">&#x02212;0.00712</td><td align="char">0.1028</td><td align="char">0.13317</td><td align="char">0.0920</td><td align="char">&#x02212;0.03339</td><td align="char">0.1140</td><td align="char">&#x02212;0.38094</td><td align="char">0.1357</td><td align="char">&#x02212;0.00189</td><td align="char">0.0408</td></tr><tr><td>Gestational age (shifted)</td><td align="char">&#x02212;0.00760</td><td align="char">0.0064</td><td align="char">&#x02212;0.06247</td><td align="char">0.0053</td><td align="char">0.15138</td><td align="char">0.0095</td><td align="char">0.36286</td><td align="char">0.0264</td><td align="char">0.04084</td><td align="char">0.0030</td></tr><tr><td>Gestational age (shifted) squared</td><td/><td/><td/><td/><td/><td/><td align="char">&#x02212;0.01379</td><td align="char">0.0010</td><td/><td/></tr><tr><td>Maternal age</td><td align="char">&#x02212;0.00374</td><td align="char">0.0124</td><td align="char">&#x02212;0.01508</td><td align="char">0.0111</td><td align="char">&#x02212;0.00339</td><td align="char">0.0136</td><td align="char">0.01062</td><td align="char">0.0163</td><td align="char">&#x02212;0.00060</td><td align="char">0.0049</td></tr><tr><td>Enrolment BMI</td><td align="char">0.00301</td><td align="char">0.0165</td><td align="char">0.00489</td><td align="char">0.0147</td><td align="char">&#x02212;0.01953</td><td align="char">0.0185</td><td align="char">&#x02212;0.00981</td><td align="char">0.0218</td><td align="char">&#x02212;0.00400</td><td align="char">0.0066</td></tr><tr><td>Gravidity</td><td align="char">&#x02212;0.01963</td><td align="char">0.0287</td><td align="char">0.02506</td><td align="char">0.0259</td><td align="char">&#x02212;0.02451</td><td align="char">0.0319</td><td align="char">0.06139</td><td align="char">0.0379</td><td align="char">&#x02212;0.01134</td><td align="char">0.0114</td></tr><tr><td>Gestational age: treatment arm interaction</td><td align="char">0.00113</td><td align="char">0.0063</td><td align="char">&#x02212;0.00296</td><td align="char">0.0064</td><td align="char">0.00519</td><td align="char">0.0059</td><td align="char">&#x02212;0.00384</td><td align="char">0.0087</td><td align="char">&#x02212;0.00445</td><td align="char">0.0026</td></tr><tr><td>Number of subjects</td><td colspan="2">311</td><td colspan="2">303</td><td colspan="2">311</td><td colspan="2">311</td><td colspan="2">311</td></tr><tr><td>Observations</td><td colspan="2">1080</td><td colspan="2">1025</td><td colspan="2">1080</td><td colspan="2">1080</td><td colspan="2">1061</td></tr><tr><td>LR Test against Null Model</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 0.0, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 2.128, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 0.0878, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 7.892, p &#x0003c; 0.005*</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 0.0025, p &#x0003e; 0.05</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tblS4" position="anchor"><label>Table S4</label><caption><p>Linear mixed effects models of angiogenic markers and stillbirth</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Ang-1<hr/></th><th colspan="2">Ang-2<hr/></th><th colspan="2">sFlt-1<hr/></th><th colspan="2">PlGF<hr/></th><th colspan="2">sEng<hr/></th></tr><tr><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th><th>Beta</th><th>SE</th></tr></thead><tbody><tr><td><bold>Fixed Terms</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>(Intercept)</td><td align="char">2.14007</td><td align="char">0.4468</td><td align="char">2.20069</td><td align="char">0.3979</td><td align="char">&#x02212;0.40889</td><td align="char">0.5146</td><td align="char">&#x02212;3.14340</td><td align="char">0.5889</td><td align="char">2.12762</td><td align="char">0.1788</td></tr><tr><td>Stillbirth</td><td align="char">0.01616</td><td align="char">0.2756</td><td align="char">&#x02212;0.24706</td><td align="char">0.2320</td><td align="char">&#x02212;0.34066</td><td align="char">0.3784</td><td align="char">&#x02212;1.66380</td><td align="char">0.3520</td><td align="char">0.26459</td><td align="char">0.1110</td></tr><tr><td>Gestational age (shifted)</td><td align="char">&#x02212;0.00887</td><td align="char">0.0064</td><td align="char">&#x02212;0.06329</td><td align="char">0.0053</td><td align="char">0.15278</td><td align="char">0.0093</td><td align="char">0.36828</td><td align="char">0.0259</td><td align="char">0.04064</td><td align="char">0.0030</td></tr><tr><td>Gestational age (shifted) squared</td><td/><td/><td/><td/><td/><td/><td align="char">&#x02212;0.01405</td><td align="char">0.0010</td><td/><td/></tr><tr><td>Maternal age</td><td align="char">&#x02212;0.00309</td><td align="char">0.0120</td><td align="char">&#x02212;0.01486</td><td align="char">0.0109</td><td align="char">&#x02212;0.00362</td><td align="char">0.0132</td><td align="char">0.00881</td><td align="char">0.0156</td><td align="char">&#x02212;0.00154</td><td align="char">0.0048</td></tr><tr><td>Enrolment BMI</td><td align="char">0.00369</td><td align="char">0.0161</td><td align="char">0.00480</td><td align="char">0.0145</td><td align="char">&#x02212;0.01959</td><td align="char">0.0181</td><td align="char">&#x02212;0.00876</td><td align="char">0.0208</td><td align="char">&#x02212;0.00297</td><td align="char">0.0064</td></tr><tr><td>Gravidity</td><td align="char">&#x02212;0.02331</td><td align="char">0.0278</td><td align="char">0.01885</td><td align="char">0.0253</td><td align="char">&#x02212;0.02359</td><td align="char">0.0308</td><td align="char">0.07530</td><td align="char">0.0359</td><td align="char">&#x02212;0.01047</td><td align="char">0.0111</td></tr><tr><td>Gestational age: treatment arm interaction</td><td align="char">0.00149</td><td align="char">0.0062</td><td align="char">&#x02212;0.00316</td><td align="char">0.0063</td><td align="char">0.00427</td><td align="char">0.0058</td><td align="char">&#x02212;0.00421</td><td align="char">0.0085</td><td align="char">&#x02212;0.00471</td><td align="char">0.0026</td></tr><tr><td>Number of subjects</td><td colspan="2">320</td><td colspan="2">312</td><td colspan="2">320</td><td colspan="2">320</td><td colspan="2">320</td></tr><tr><td>Observations</td><td colspan="2">1104</td><td colspan="2">1049</td><td colspan="2">1104</td><td colspan="2">1104</td><td colspan="2">1085</td></tr><tr><td>LR Test against Null Model</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 0.0045, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 1.129, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 0.819, p &#x0003e; 0.05</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 21.595, p &#x0003c; 0.0001*</td><td colspan="2">&#x003c7;<sup>2</sup>(1) = 5.6717, p &#x0003c; 0.02*</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Conroy et&#x000a0;al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017</italic>.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="appsec2" sec-type="supplementary-material"><title>Supplementary Data</title><p id="p0135"><supplementary-material content-type="local-data" id="mmc1"><caption><title>Video</title></caption><media xlink:href="mmc1.mp4"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Supplementary Data</title></caption><media xlink:href="mmc2.pptx"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgment</title><p>This study would not have been possible without the participation, input, and work of the mothers, field teams, nursing and medical staff, and members of the Infectious Diseases Research Collaboration involved in this trial. We would like to thank Mr Ssemanda Cephus for assistance with plate mapping and aliquoting samples.</p></ack><fn-group><fn id="d31e1855"><p id="ntpara0015">This work was supported by Bill &#x00026; Melinda Gates Foundation; Family Health. Grand Challenges in Global Health: Preventing Preterm Birth Initiative through a contract to the Global Alliance to Prevent Preterm Birth and Stillbirth (GAPPS) grant no. 12003 (K.C.K.); the Canadian Institutes of Health Research (CIHR) MOP-115160, 136813, 13721 and a CIHR Foundation grant-FDN-148493 (K.C.K.), Fellowship (C.R.M. and A.L.C.) and Canada Research Chair (K.C.K.). The parent trial was supported by a grant from the <italic>Eunice Kennedy Shriver</italic> National Institute of Child Health and Human Development at the National Institutes of Health (P01 HD059454 to D.V.H.). AbbVie Pharmaceuticals donated the lopinavir/ritonavir (Aluvia) used in this study. The sponsors had no role in the study design; in the collection, analysis, or interpretation of data; the writing of the report; or the decision to submit the article for publication.</p></fn><fn id="d31e1861"><p id="ntpara0020">The authors report no conflict of interest.</p></fn><fn id="d31e1864"><p id="ntpara0025"><bold>Cite this article as:</bold> Conroy AL, McDonald CR, Gamble JL, et&#x000a0;al. Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. Am J Obstet Gynecol 2017;217:684.e1-14.</p></fn></fn-group></back></article>